Sorafenib for the treatment of solid malignancies: what about the cancer microenvironment?
Ciprian Tomuleasa, Andrei Cucuianu, Mihaela Aldea, Ioana Berindan-NeagoeResearch Center of Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, RomaniaWe have read with great interest the study of Kim et al, recently published in the Inter...
Guardado en:
Autores principales: | Tomuleasa C, Cucuianu A, Aldea M, Berindan-Neagoe I |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5a06532947f34f448e28bf6648b245ac |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dose intensity and autologous stem cell transplantation as salvage therapy for pediatric primary CNS malignancies
por: Kojima S, et al.
Publicado: (2014) -
MRI-based identification of undifferentiated cells: looking at the two faces of Janus
por: Tomuleasa C, et al.
Publicado: (2014) -
Nanopharmacology in translational hematology and oncology
por: Tomuleasa C, et al.
Publicado: (2014) -
Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Junji Furuse
Publicado: (2008) -
Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles
por: Zhang H, et al.
Publicado: (2012)